Tag: Patients
Search News
Celebrating a New Milestone at the PCRF Tissue Bank
29th September 2022
Recently, the PCRF Tissue Bank registered its 1,000th tissue donor, reaching a new milestone. We spoke with Amina Saad, who is responsible for over 660 donor registrations, including the Tissue Bank’s 1,000th registration, about her role as a Tissue Collection Officer within the Tissue Bank team.
Read more
PCRF’s national pancreas tissue bank extends access to precious pancreas samples
26th August 2022
The world’s first national pancreas tissue bank has recently opened its stores to UK-based researchers to access high-quality pancreas samples that will facilitate vital research into improving the diagnosis and treatment of pancreatic cancer.
Read more
Celebrating 10 years of the Breast Cancer Now Tissue Bank
19th August 2022
This summer, the Breast Cancer Now Tissue Bank is celebrating 10 years of enabling vital breast cancer research. Since opening in 2012, the Tissue Bank has provided researchers across the globe with access to high-quality breast tissue, breast cells and blood samples from breast cancer patients, driving advances in breast cancer diagnosis and treatment.
Read more
Study suggests simple blood test could help to monitor pancreatic cancer patients
28th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have found it is possible to identify and track genetic variations in the tumours of patients with pancreatic cancer using a simple blood test.
Read more
Clinical study to investigate new personalised treatment for ovarian cancer
14th March 2022
Dr Michelle Lockley from Barts Cancer Institute at Queen Mary University of London has received funding from Barts Charity and the Anticancer Fund to investigate a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy.
Read more
Immunotherapy significantly reduces recurrence in aggressive breast cancer
10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more